The company announced it has concluded development of the plasma kallikrein inhibitor, which was being studied to treat diabetic macular edema.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
The company announced it has concluded development of the plasma kallikrein inhibitor, which was being studied to treat diabetic macular edema.